Literature DB >> 27342750

Exploration of GGTase-I substrate requirements. Part 1: Synthesis and biochemical evaluation of novel aryl-modified geranylgeranyl diphosphate analogs.

Kayla J Temple1, Elia N Wright2, Carol A Fierke3, Richard A Gibbs4.   

Abstract

Protein geranylgeranylation is a type of post-translational modification that aids in the localization of proteins to the plasma member where they elicit cellular signals. To better understand the isoprenoid requirements of GGTase-I, a series of aryl-modified geranylgeranyl diphosphate analogs were synthesized and screened against mammalian GGTase-I. Of our seven-member library of compounds, six analogs proved to be substrates of GGTase-I, with 6d having a krel=1.93 when compared to GGPP (krel=1.0).
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aryl-modified GGPP analogs; GGTase-I; Geranylgeranylation; Post-translational modification; Protein prenylation

Mesh:

Substances:

Year:  2016        PMID: 27342750      PMCID: PMC4955810          DOI: 10.1016/j.bmcl.2016.06.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

Review 1.  Protein prenylation: a pivotal posttranslational process.

Authors:  Robert Roskoski
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

2.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

3.  S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.

Authors:  Joel A Bergman; Kalub Hahne; Jiao Song; Christine A Hrycyna; Richard A Gibbs
Journal:  ACS Med Chem Lett       Date:  2011-11-28       Impact factor: 4.345

Review 4.  Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I.

Authors:  Kimberly T Lane; Lorena S Beese
Journal:  J Lipid Res       Date:  2006-02-13       Impact factor: 5.922

5.  Synthesis and evaluation of 3- and 7-substituted geranylgeranyl pyrophosphate analogs.

Authors:  Michelle Maynor; Sarah A Scott; Emily L Rickert; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2008-02-12       Impact factor: 2.823

6.  Coupling of isoprenoid triflates with organoboron nucleophiles: synthesis and biological evaluation of geranylgeranyl diphosphate analogues.

Authors:  YongQi Mu; Lisa M Eubanks; C Dale Poulter; Richard A Gibbs
Journal:  Bioorg Med Chem       Date:  2002-05       Impact factor: 3.641

7.  Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.

Authors:  H R Ashar; L James; K Gray; D Carr; S Black; L Armstrong; W R Bishop; P Kirschmeier
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

8.  12/15-Lipoxygenase gene knockout severely impairs ischemia-induced angiogenesis due to lack of Rac1 farnesylation.

Authors:  Nikhlesh K Singh; Venkatesh Kundumani-Sridharan; Gadiparthi N Rao
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

9.  Synthesis of Farnesol Analogues through Cu(I)-Mediated Displacements of Allylic THP Ethers by Grignard Reagents.

Authors:  Mark F. Mechelke; David F. Wiemer
Journal:  J Org Chem       Date:  1999-06-25       Impact factor: 4.354

10.  Structure of mammalian protein geranylgeranyltransferase type-I.

Authors:  Jeffrey S Taylor; T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  EMBO J       Date:  2003-11-17       Impact factor: 11.598

View more
  1 in total

1.  Synthesis of Non-natural, Frame-Shifted Isoprenoid Diphosphate Analogues.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Org Lett       Date:  2016-11-14       Impact factor: 6.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.